Search results for "immunotherapy"

showing 10 items of 830 documents

Etude de la régulation transcriptionnelle des lymphocytes T CD4 dans un contexte de cancer : application en immunothérapie anticancéreuse

2015

Immune surveillance of tumors is based on the ability of effector cells of the immune system to detect and eliminate the cancer cells. Notwithstanding, the complete and spontaneous regression of established cancers was observed only in very few cases. The failure of cancer resolution by the immune system could result from the combination of several factors: i) inadequate immune response related to a low tumor immunogenicity, ii) incompetent immune system consecutively to induced or acquired immunodeficiencies and iii) the selection of resistant tumor variants able to thwart immune surveillance or subverting immune responses. Developing novel cancer immunotherapy strategies leading to potent…

Immunothérapie anticancéreuse[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyRégulation transcriptionnelleCancer immunotherapyIRF1CD4 T cell differentiationDifférenciation lymphocytaire T CD4DHAIFR1Transcriptional regulation[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Cytokine therapy of neoplastic and inflammatory disease.

1993

Cytokines have been widely tested in clinical trials during recent years and beneficial responses have been observed in a variety of malignant, infectious and autoimmune diseases. Interferon-alpha induces remissions in patients with certain hematological malignancies such as hairy cell leukemia and chronic myelogenous leukemia. A proportion of patients with chronic viral hepatitis is cured upon application of interferon-alpha. Treatment with interferon-gamma reduces the number of infections in patients with chronic granulomatous disease. In addition, several chronic infections with intracellular pathogens also respond to treatment with this cytokine. With the exception of some patients with…

InflammationCytokine Therapybusiness.industrymedicine.medical_treatmentImmunologyGeneral MedicineImmunotherapyDiseasemedicine.diseaseRecombinant ProteinsCytokineChronic granulomatous diseaseInterferonNeoplasmsImmunologymedicineImmunology and AllergyCytokinesHumansHairy cell leukemiabusinessChronic myelogenous leukemiamedicine.drugInternational archives of allergy and immunology
researchProduct

Modification of the innate immune function of dendritic cells by allergen-specific immunotherapy

2009

Innate immune systembusiness.industryImmunologyImmunologyInnate lymphoid cellCCL18Immunology and AllergySpecific immunotherapyMedicinebusinessFunction (biology)Clinical & Experimental Allergy
researchProduct

Interleukin-2 immediate type hypersensitivity?

2008

Two patients with metastatic malignant melanoma developed immediate type hypersensitivity-like symptoms while being treated with recombinant interleukin-(IL-)2 immunotherapy. Both patients showed positive skin prick tests to IL-2, enhanced basophil degranulation in vitro and responded to anti-histamines, but laboratory investigations suggested an IgE-independent, pseudoallergic mast cell degranulation against IL-2.

Interleukin 2AdultMalemedicine.medical_treatmentDermatologyImmunoglobulin EBasophil degranulationlaw.inventionlawmedicineHumansbiologybusiness.industryDegranulationImmunotherapyMiddle Agedmedicine.diseaseIn vitroImmunologybiology.proteinRecombinant DNAInterleukin-2FemaleDrug Eruptionsbusinessmedicine.drugType I hypersensitivityJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
researchProduct

Human interleukin 2: molecular biology, physiology and clinical possibilities.

1986

Interleukin 2Antigens Differentiation T-Lymphocytemedicine.medical_treatmentT-LymphocytesImmunologyPhysiologyGraft vs Host DiseaseCyclosporinsBiologyInterleukine 2MiceNeoplasmsmedicineImmune ToleranceImmunology and AllergyAnimalsHumansReceptors ImmunologicBone Marrow TransplantationMacrophagesLymphokineImmunization PassiveAntibodies MonoclonalImmunosuppressionReceptors Interleukin-2HematologyImmunotherapyRecombinant ProteinsKiller Cells NaturalImmunologyAntigens SurfaceInterleukin-2medicine.drugImmunobiology
researchProduct

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

2007

Abstract The increasing evidence that γδ T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the γδ T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood γδ cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-te…

Interleukin 2MaleCancer ResearchNeoplasms Hormone-Dependentmedicine.medical_treatmentT cellT-LymphocytesAntineoplastic AgentsLymphocyte ActivationZoledronic AcidArticleMetastatic carcinomaProstate cancerAntigenMedicineHumansAgedAged 80 and overSalvage TherapyBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryRemission InductionImidazolesProstatic NeoplasmsReceptors Antigen T-Cell gamma-deltaImmunotherapyMiddle Agedmedicine.diseaseVγ9Vδ2 T cellsZoledronateIL-2Hormone-refractory prostate cancerImmunotherapyCytokinemedicine.anatomical_structureTreatment OutcomeOncologyImmunologyFeasibility StudiesInterleukin-2Tumor necrosis factor alphaDrug Therapy CombinationImmunotherapybusinessmedicine.drug
researchProduct

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk …

1998

To improve the complete remission (CR) rate and to prolong CR duration in patients with advanced MDS, AML evolving from MDS, and secondary AML, a phase-III trial of aggressive chemotherapy followed by G-CSF was initiated in January 1992. Pts. achieving a CR were randomized to receive either high-dose or low-dose IL-2 to evaluate the potential of this cytokine to eliminate residual leukemic cells and to prolong the CR duration.

Interleukin 2Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMyeloid leukemiaImmunotherapyCytokinehemic and lymphatic diseasesInternal medicinemedicineIdarubicinbusinessAmsacrineARA-C/VP-16medicine.drug
researchProduct

Induction Therapy with Idarubicin, Ara-C, and VP-16, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for High-Risk AML

1996

Aggressive chemotherapy followed by administration of G-CSF and maintenance therapy with interleukin-2 was evaluated in 16 patients with advanced myelodxysplastic syndrome, 47 patients with AML evolving from myelodysplastic syndromes, 3 patients with subacute myeloid leukemia and 5 patients with secondary AML. Median age was 59 years (range: 23 to 76 years). All patients achieving a complete remission (CR) after two induction courses went on to receive two consolidation courses, to be followed by randomization to either high-dose or low-dose IL-2 to evaluate the potential of IL-2 to eliminate residual leukemic cells and to prolong the duration of CR. Patients ≤ age 55 with an HLA identical …

Interleukin 2medicine.medical_specialtyAcute leukemiaChemotherapyRandomizationbusiness.industrymedicine.medical_treatmentMyelodysplastic syndromesImmunotherapymedicine.diseaseGastroenterologyMaintenance therapyInternal medicinemedicineIdarubicinbusinessmedicine.drug
researchProduct

<p>Isolation and Functions of Extracellular Vesicles Derived from Parasites: The Promise of a New Era in Immunotherapy, Vaccination, and Diagno…

2020

Experimental and epidemiological evidence shows that parasites, particularly helminths, play a central role in balancing the host immunity. It was demonstrated that parasites can modulate immune responses via their excretory/secretory (ES) and some specific proteins. Extracellular vesicles (EVs) are nano-scale particles that are released from eukaryotic and prokaryotic cells. EVs in parasitological studies have been mostly employed for immunotherapy of autoimmune diseases, vaccination, and diagnosis. EVs can carry virulence factors and play a central role in the development of parasites in host cells. These molecules can manipulate the immune responses through transcriptional changes. Moreo…

Isolation (health care)medicine.medical_treatmentBiophysicsPharmaceutical ScienceVirulenceBioengineering02 engineering and technologyBiology010402 general chemistry01 natural sciencesExtracellular vesiclesBiomaterialsImmune systemImmunityDrug DiscoverymedicineOrganic ChemistryGeneral MedicineImmunotherapy021001 nanoscience & nanotechnologybiology.organism_classification0104 chemical sciencesVaccinationImmunologyProtozoa0210 nano-technologyInternational Journal of Nanomedicine
researchProduct

Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.

2010

Monoclonal antibodies (mAbs) constitute the most rapidly growing class of human therapeutics and the second largest class of drugs after vaccines. The treatment of B-cell malignancies and HER2/Neu(+) breast cancer has benefited considerably from the use of therapeutic mAbs, either alone or in combination with standard chemotherapy. Frequent relapses, however, demonstrate that the bioactivity of these mAbs is still suboptimal. The concept of improving the anti-tumor activity of mAbs is well established and potentiating the cytotoxicity induced by anticancer mAbs can be achieved by strategies that target the downstream cytolytic effector cells. The recruitment of Fcγ receptor-dependent functi…

Killer Cells NaturalReceptor ErbB-2NeoplasmsT-LymphocytesReceptors IgGAntibody-Dependent Cell CytotoxicityAnimalsAntibodies MonoclonalHumansγδ T Cells ImmunotherapyReceptors Antigen T-Cell gamma-deltaImmunotherapyLymphocyte ActivationCurrent molecular medicine
researchProduct